70PD EFFECT OF ENOBOSARM, A SELECTIVE ANDROGEN RECEPTOR MODULATOR, IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH MUSCLE WASTING IN A PHASE IIB TRIAL von Croot, C.C, Johnston, M.A, Steiner, M.S, Hancock, M.L, Somer, B.G

Volltext

1387P Final analysis of the phase Ib/II study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent von Markowski, M.C., Eisenberger, M., Pieczonka, C., Rodriguez, D., Barnette, K.G., Getzenberg, R.H., Steiner, M.S., Saltzstein, D.R., Antonarakis, E.S., Tutrone, R.F.

Volltext

206TiP Randomized, multicenter, international phase III ARTEST study to evaluate enobosarm versus active control for the treatment of AR+ ER+ HER2- metastatic breast cancer in pati... von Brufsky, A., Linden, H., Rugo, H.S., Vogel, C., O'Shaughnessy, J., Getzenberg, R.H., Barnette, K.G., Rodriguez, D., Steiner, M.S., Mayer, E.

Volltext

Sabizabulin has both cytotoxic and cytostatic activity in Phase 1b/2 clinical of men with metastatic castration resistant prostate cancer who progressed on androgen receptor target... von Markowski, M., Eisenberger, M., Pieczonka, C., Getzenberg, R.H., Rodriguez, D., Barnette, K.G., Steiner, M.S., Saltzstein, D., Antonarakis, E., Tutrone, R.

Volltext

578MO Phase Ib/II study of sabizabulin (VERU-111), an androgen receptor transport disruptor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an andro... von Markowski, M.C., Eisenberger, M., Pieczonka, C.M., Getzenberg, R.H., Rodriguez, D., Barnette, K.G., Steiner, M.S., Saltzstein, D.R., Antonarakis, E.S., Tutrone, R.

Volltext

Clinical study of VERU-111, an oral cytoskeletal disruptor in men with metastatic Castration Resistant Prostate Cancer (mCRPC) who failed an androgen receptor targeting agent von Getzenberg, R., Markowski, M.C., Tutrone, R., Eisenberger, M.A., Pieczonka, C., Rodriguez, D., Barnette, K.G., Steiner, M.S., Saltzstein, D.R., Antonarakis, E.S.

Volltext

615MO Phase Ib/II study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent von Markowski, M., Eisenberger, M.A., Tutrone, R., Pieczonka, C., Getzenberg, R.H., Rodriguez, D., Barnette, K.G., Steiner, M.S., Saltzstein, D.R., Antonarakis, E.S.

Volltext

Bone morphogenetic protein-6 expression in normal and malignant prostate von Barnes, J, Anthony, C T, Wall, N, Steiner, M S

Volltext

GTX-758, An Oral ERa Agonist, Increases Sex Hormone Binding Globulin, Reduces Free T and Decreases PSA in Patients with Castration Resistant Prostate Cancer von Steiner, M.S., Taylor, R.P., Getzenberg, R.H., Johnston, M.A., Hancock, M., Dalton, J.T.

Volltext

102 GTx-758, an ERα agonist, reduces serum free testosterone lower than can be achieved by leuprolide with a significantly lower rate of hot flashes in men with advanced prostate c... von Getzenberg, R.H, Coss, C.C, Hancock, M.L, Dalton, J.T, Steiner, M.S

Volltext

863 Low dose GTx-758 decreases free testosterone to levels similar to orchiectomy in men with metastatic castration resistant prostate cancer (mCRPC) von Getzenberg, R.H, Yu, E.Y, Smith, J.A, Hancock, M.L, Tutrone, R, Flaig, T.W, Westenfelder, K.R, Szucs, M, Dalton, J.T, Steiner, M.S

Volltext

1005 - VERU-111, a novel oral inhibitor of α and β tubulin, inhibits tumor growth in the human castration-resistant AR variant prostate cancer (PCa) model 22Rv1 von Getzenberg, R., Markowski, M.M., Eisenberger, M.A., Steiner, M.S., Antonarakis, E.S.

Volltext

VERU-111, a novel oral inhibitor of α and β tubulin, inhibits tumor growth in the human castration-resistant AR variant prostate cancer (PCa) model 22Rv1 von Getzenberg, R., Markowski, M.M., Eisenberger, M.A., Steiner, M.S., Antonarakis, E.S.

Volltext

Transforming growth factor-? and prostate cancer von Steiner, M.S.

Volltext

PT118 - Design of phase 1b/2 study of oral VERU-111, an α and β-tubulin inhibitor, for the treatment of metastatic castration and androgen blocking agent resistant prostate cancer... von Getzenberg, R., Markowski, M.C., Eisenberger, M.A., Antonarakis, E.S., Yu, E.Y., Barnette, G., Rodriguez, D., Steiner, M.S.

Volltext

Design of phase 1b/2 study of oral VERU-111, an α and β-tubulin inhibitor, for the treatment of metastatic castration and androgen blocking agent resistant prostate cancer von Getzenberg, R., Markowski, M.C., Eisenberger, M.A., Antonarakis, E.S., Yu, E.Y., Barnette, G., Rodriguez, D., Steiner, M.S.

Volltext

An overview on selective androgen receptor modulators: Focus on enobosarm von Jones, A., Coss, C.C., Steiner, M.S., Dalton, J.T.

Volltext

An overview on selective androgen receptor modulators: Focus on enobosarm von Jones, A., Coss, C.C., Steiner, M.S., Dalton, J.T.

Volltext

Peptide growth factors in urology von Steiner, M.S.

Volltext

Peptide growth factors in urology von Steiner, M S

Volltext